CompletedNot Applicable

Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory

Kazakhstan226 participantsStarted 2020-01-13

Plain-language summary

Depression and anxiety in female patients with cancer are serious comorbidities that affect the quality of life for patients and their survival rates as they have poorer health outcomes. This validation study is a part of the study on the prevalence of depression and anxiety among breast cancer patients. This study aims to investigate the validity of the Kazakh and Russian versions of the Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI) among female cancer patients in Almaty, Kazakhstan.

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult female patients between 18 and 65 years of age with a primary diagnosis of breast cancer; ovarian cancer; cervical cancer; colon cancer; lung cancer; * Russian or Kazakh language fluency; * consent to participate; Exclusion Criteria: * history of diagnosed depression or anxiety; * current use of antidepressants; * referral to palliative care

What they're measuring

BDI-II Score at Baseline:

Timeframe: Baseline

BDI-II Score on day 14

Timeframe: Day 14

BAI Score at Baseline

Timeframe: Baseline

BAI Score Day 14

Timeframe: Day 14

ICD-10 diagnosis at baseline

Timeframe: Baseline

ICD-10 diagnosis on Day 14

Timeframe: Day 14

Internal consistency of the BAI

Timeframe: Day 14

Internal consistency of the BDI-II

Timeframe: Day 14

Test - retest reliability of the BDI-II questtionaire

Timeframe: Day 14

Trial details

NCT IDNCT04630327

SponsorKazakh Medical University of Continuing Education

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-28

View on ClinicalTrials.gov More Depression trials